Evidence map›Paper›PMID 39323343›Full record

ReviewCurrent drug targets2025

Targeting SERCA2 in Anti-Tumor Drug Discovery.

Wanqian Song, Qiuju Zhang, Zhiyong Cao, Guo Jing, Tiancheng Zhan, Yongkang Yuan, Ning Kang, Qiang Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanqian SongSchool of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.ORCID 0009-0000-4654-0385
Qiuju ZhangSchool of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Zhiyong CaoSchool of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Guo JingSchool of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.ORCID 0009-0002-9728-2915
Tiancheng ZhanSchool of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.ORCID 0009-0001-1026-1410
Yongkang YuanSchool of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.ORCID 0009-0008-6065-1573
Ning KangSchool of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.ORCID 0000-0002-4953-0462
Qiang ZhangSchool of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.ORCID 0000-0002-0691-7448

Funding

Annual Graduate Students Innovation Fund, School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China ZXYCXLX202110, ZXYCXLX202104National College Students Innovation and Entrepreneurship Training Program 202310063010National Natural Science Foundation of China 82104461, 82274221Tianjin Graduate Students Research Innovation Program 2022SKY231, 2022BKY181
6 · The paper itself

Abstract

SERCA2, a P-type ATPase located on the endoplasmic reticulum of cells, plays an important role in maintaining calcium balance within cells by transporting calcium from the cytoplasm to the endoplasmic reticulum against its concentration gradient. A multitude of studies have demonstrated that the expression of SERCA2 is abnormal in a wide variety of tumor cells. Consequently, research exploring compounds that target SERCA2 may offer a promising avenue for the development of novel anti-tumor drugs. This review has summarized the anti-tumor compounds targeting SERCA2, including thapsigargin, dihydroartemisinin, curcumin, galangin, etc. These compounds interact with SERCA2 on the endoplasmic reticulum membrane, disrupting intracellular calcium ion homeostasis, leading to tumor cell apoptosis, autophagy and cell cycle arrest, ultimately producing anti-tumor effects. Additionally, several potential research directions for compounds targeting SERCA2 as clinical anti-cancer drugs have been proposed in the review. In summary, SERCA2 is a promising anti-tumor target for drug discovery and development.

Indexed as

Antineoplastic AgentsDrug DiscoveryNeoplasmsSarcoplasmic Reticulum Calcium-Transporting ATPasesAnimalsApoptosisAutophagyCalciumHumansMolecular Targeted TherapyAntineoplastic AgentsATP2A2 protein, humanCalciumSarcoplasmic Reticulum Calcium-Transporting ATPasesautophagycalcium ioncell apoptosiscell cycle arrest.endoplasmic reticulum stressSarcoplasmic reticulum/endoplasmic reticulum calcium ATPase

Identifiers

PMID39323343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.